title: Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.
abstract: Somatostatin receptor scintigraphy (SRS) is positive in approximately 80% of all patients who have been found to have neuroendocrine (NE) gastroenteropancreatic (GEP) tumors. The reasons for negative results are unclear. The aim of the present study was identification of the specific somatostatin receptor (SSTR) subtypes that are responsible for the in vivo binding of the widely used somatostatin (SST) analogues octreotide and lanreotide in human neuroendocrine gastroenteropancreatic tumors. Ten patients were subjected to SRS with radiolabeled octreotide. Following surgical resection, tumor tissues were analyzed for SSTR subtype mRNA expression by the reverse transcription-polymerase chain reaction (RT-PCR). In addition, SSTR subtype transcripts were investigated by Northern blot analysis and RT-PCR in neuroendocrine tumor cell lines. Expression of SSTR at the protein level was studied by chemical cross-linking experiments. Three patients were negative by SRS. However, RT-PCR revealed most prominently SSTR 2 expression in all tumor specimens. In addition, all tumor tissues analyzed by chemical crosslinking exhibited SST-14 binding sites, indicating that at least some NE tumors were false-negative on SRS.
authors.affiliation: Freie Universität Berlin, Universitätsklinikum Rudolf Virchow, Department of Surgery, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Jonas
authors.forename: M
authors.initials: M
authors.lastname: John
authors.forename: J
authors.initials: J
authors.lastname: Boese-Landgraf
authors.forename: R
authors.initials: R
authors.lastname: Häring
authors.forename: G
authors.initials: G
authors.lastname: Prevost
authors.forename: F
authors.initials: F
authors.lastname: Thomas
authors.forename: S
authors.initials: S
authors.lastname: Rosewicz
authors.forename: E O
authors.initials: EO
authors.lastname: Riecken
authors.forename: B
authors.initials: B
authors.lastname: Wiedenmann
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics; D015152:Blotting, Northern; D002460:Cell Line; D005770:Gastrointestinal Neoplasms / Q000235:genetics* / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D006801:Humans; D018358:Neuroendocrine Tumors / Q000235:genetics* / Q000473:pathology; D015282:Octreotide / Q000493:pharmacokinetics; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000473:pathology; D010456:Peptides, Cyclic / Q000493:pharmacokinetics; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D017481:Receptors, Somatostatin / Q000145:classification / Q000235:genetics*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D014158:Transcription, Genetic / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; D012333:RNA, Messenger; D017481:Receptors, Somatostatin; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide